No change in health-related quality of life for at-risk U.S. women and men starting HIV pre-exposure prophylaxis (PrEP): Findings from HPTN 069/ACTG A5305. by Shashi N Kapadia, Chunyuan Wu, Kenneth H Mayer, Timothy J Wilkin, K Rivet Amico, Raphael J Landovitz, Adriana Andrade, Ying Q Chen, Wairimu Chege, Marybeth McCauley, Roy M Gulick, Bruce R Schackman

Get full text

HPTN 083‐02: factors influencing adherence to injectable PrEP and retention in an injectable PrEP study by Christina Psaros, Georgia R. Goodman, Jasper S. Lee, Whitney Rice, Colleen F. Kelley, Temitope Oyedele, Lara E. Coelho, Nittaya Phanuphak, Yashna Singh, Keren Middelkoop, Sam Griffith, Marybeth McCauley, James Rooney, Alex R. Rinehart, Jesse Clark, Vivian Go, Jeremy Sugarman, Sheldon D. Fields, Adeola Adeyeye, Beatriz Grinsztejn, Raphael J. Landovitz, Steven A. Safren, the HPTN 083‐02 Study Team

Get full text

Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial. by Raphael J Landovitz, Sue Li, Beatriz Grinsztejn, Halima Dawood, Albert Y Liu, Manya Magnus, Mina C Hosseinipour, Ravindre Panchia, Leslie Cottle, Gordon Chau, Paul Richardson, Mark A Marzinke, Craig W Hendrix, Susan H Eshleman, Yinfeng Zhang, Elizabeth Tolley, Jeremy Sugarman, Ryan Kofron, Adeola Adeyeye, David Burns, Alex R Rinehart, David Margolis, William R Spreen, Myron S Cohen, Marybeth McCauley, Joseph J Eron

Get full text